Teleflex Receives Historic FDA Approval for EZPLAZ™ Freeze Dried Plasma, Expanding Emergency Blood Transfusion Options
Teleflex Incorporated, a global leader in medical technology and innovative healthcare solutions, has announced a landmark achievement with the U.S. Food and Drug Administration (FDA) granting Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP). The approval marks a significant milestone for both the company and emergency medicine, as EZPLAZ™ becomes the first FDA-licensed freeze-dried plasma product available in the United States. It also represents the first biologics license for a blood component awarded to Teleflex.
The approval introduces an innovative plasma product designed to improve access to life-saving blood component therapy in situations where rapid treatment is essential and conventional plasma products are unavailable. EZPLAZ™ FDP is approved for transfusion in adult patients experiencing bleeding-related conditions that require replacement of plasma coagulation factors, including uncontrolled hemorrhage, when standard plasma products cannot be accessed.
A New Option for Emergency Plasma Transfusion
The availability of EZPLAZ™ Freeze Dried Plasma addresses a longstanding challenge in emergency medicine—providing plasma quickly in environments where traditional frozen plasma is difficult or impossible to use.
Unlike conventional plasma products that require frozen storage, lengthy thawing procedures, and specialized refrigeration equipment, EZPLAZ™ is shelf-stable and can be rapidly prepared for transfusion. This capability makes it particularly valuable in emergency medical situations where every minute can determine patient survival.
Potential settings where EZPLAZ™ may be used include:
- Ground emergency medical services
- Air ambulance transport
- Emergency departments
- Trauma centers
- Military combat operations
- Remote healthcare environments
- Disaster response and humanitarian missions
By simplifying plasma storage and administration, the product has the potential to significantly improve access to clotting factor replacement during critical bleeding events.
First FDA-Licensed Freeze-Dried Plasma
Freeze-dried plasma has long been viewed as an important advancement in trauma medicine because of its portability and ease of use. Although certain freeze-dried plasma products have previously been available in limited circumstances under Emergency Use Authorization (EUA), none had received full FDA biologics licensure until now.
Teleflex’s approval establishes EZPLAZ™ as the first fully licensed freeze-dried plasma product in the United States.
According to Jake Newman, President and General Manager of Global Vascular and Emergency Medicine at Teleflex, the approval represents a transformational milestone for emergency care providers.
He noted that EZPLAZ™ has the potential to enable plasma transfusion wherever it is critically needed, including prehospital environments, hospitals, and military settings.
Newman also highlighted another key innovation of the product: while previous emergency freeze-dried plasma products were packaged in fragile glass bottles, EZPLAZ™ uses a patented flexible plastic bag system that offers improved portability, durability, and ease of handling.
He described the approval as an important step in expanding Teleflex’s growing emergency medicine portfolio.
Addressing One of Trauma Care’s Greatest Challenges
Severe hemorrhage remains one of the leading causes of preventable death among both civilian trauma victims and wounded military personnel.
Rapid blood loss can quickly lead to coagulopathy—a condition in which the body’s ability to form blood clots becomes impaired. Without timely replacement of clotting factors contained in plasma, patients face significantly higher risks of organ failure and death.
Plasma contains numerous proteins that play essential roles in blood coagulation. Replacing these proteins during severe bleeding has become a cornerstone of modern trauma care and massive transfusion protocols.
However, traditional plasma products present significant logistical challenges.
Conventional fresh frozen plasma must be:
- Stored in specialized freezers
- Carefully transported under frozen conditions
- Thawed before use
- Administered within strict post-thaw time limits
These requirements often limit plasma availability outside major hospitals, particularly during emergency transport or battlefield care.
Simplifying Emergency Care
EZPLAZ™ was developed specifically to overcome many of these logistical limitations.
The product can be stored between 2°C and 25°C (36°F to 77°F), eliminating the need for continuous frozen storage.
Additional practical advantages include:
- Shelf life of approximately 12 months
- Rapid preparation
- Reconstitution in approximately one to two-and-a-half minutes
- Complete transfusion kit supplied with sterile water for injection
Each kit contains everything required to prepare the plasma for administration, allowing healthcare professionals to rapidly begin treatment without relying on specialized thawing equipment.
The combination of room-temperature storage and fast preparation makes EZPLAZ™ particularly suited for emergency settings where time and resources are limited.
Years of Collaboration with the Defense Health Agency
The development of EZPLAZ™ reflects more than a decade of collaboration between Teleflex and the U.S. government.
Recognizing the urgent need for shelf-stable plasma products that could support military operations, the Defense Health Agency (DHA) identified development of FDA-approved freeze-dried plasma as a strategic priority.
In April 2014, Vascular Solutions LLC, a wholly owned subsidiary of Teleflex, entered into a Cooperative Research and Development Agreement (CRADA) with the Defense Health Agency team now known as Warfighter Protection and Acute Care (WPAC).
The partnership focused on developing a commercially available freeze-dried plasma product capable of supporting both military and civilian trauma care.
Dr. Kendra Lawrence, Project Manager for WPAC, explained that the agency partners with industry to develop products addressing mission-critical medical priorities.
She noted that providing stable, transportable blood products to front-line military personnel remains an essential objective for improving battlefield survival.
Clinical Development Program
Teleflex led the product’s development through every major stage, including manufacturing process development, regulatory planning, clinical evaluation, and establishment of commercial manufacturing operations.
The company also prepared and supported the Investigational New Drug (IND) application necessary to conduct clinical studies evaluating the safety and effectiveness of EZPLAZ™.
According to Christopher Ross, MD, Global Medical Safety Director and Interim Head of Clinical and Medical Affairs at Teleflex, the company’s clinical development program generated the evidence required to support FDA approval.
Dr. Ross emphasized that the approval reflects the contributions of investigators, volunteer blood donors, clinical trial participants, healthcare professionals, and government collaborators who participated throughout the development process.
He described the approval as an important milestone in making freeze-dried plasma available to clinicians across the United States.
Approved Clinical Uses
The FDA has approved EZPLAZ™ Freeze Dried Plasma for transfusion in adult patients when plasma replacement is required and alternative plasma products are unavailable.
Approved clinical uses include:
- Replacement of multiple plasma coagulation factors in bleeding or preoperative patients
- Treatment of patients with liver disease or disseminated intravascular coagulation (DIC)
- Massive transfusion protocols involving clinically significant coagulation deficiencies
- Temporary reversal of warfarin anticoagulation in bleeding patients or those requiring urgent invasive procedures before vitamin K becomes effective
These indications provide physicians with an additional therapeutic option during emergencies where immediate plasma replacement is necessary.
Important Safety Considerations
As with all plasma-derived blood products, EZPLAZ™ carries important safety considerations that healthcare providers must carefully evaluate before administration.
The product should not be used in:
- Patients with known hypersensitivity to fresh frozen plasma or plasma-derived products
- Individuals with Immunoglobulin A (IgA) deficiency
Healthcare providers must also remain alert for potential transfusion-related complications.
Potential risks include:
- Hemolytic transfusion reactions resulting from ABO incompatibility
- Transfusion-related acute lung injury (TRALI)
- Allergic or hypersensitivity reactions, including anaphylaxis
- Potential transmission of infectious agents associated with human plasma
To reduce the risk of TRALI, EZPLAZ™ is manufactured exclusively using plasma collected from male donors.
Additional Clinical Precautions
Teleflex also notes that EZPLAZ™ is not intended for routine volume expansion.
Clinicians should consider alternative therapies when patients do not have documented deficiencies in plasma coagulation factors or plasma proteins.
The company further advises that specific therapies may be more appropriate in certain situations, including:
- Vitamin K for reversal of vitamin K antagonists
- Fibrinogen replacement products
- Specific coagulation factor concentrates
- Targeted reversal agents for newer anticoagulants
In patients with only mildly elevated International Normalized Ratio (INR) values, plasma transfusion may not provide clinically meaningful correction, and alternative treatment strategies should be considered.
Expanding Teleflex’s Emergency Medicine Portfolio
The FDA approval of EZPLAZ™ represents a significant strategic expansion for Teleflex beyond its established medical device portfolio.
As the company’s first licensed blood component product, EZPLAZ™ strengthens Teleflex’s position in trauma care, emergency medicine, vascular intervention, and critical care.
The combination of shelf stability, rapid preparation, innovative packaging, and FDA licensure positions the product to address an important unmet need in both civilian healthcare systems and military medicine.
With increasing emphasis on improving trauma outcomes through earlier administration of blood products, EZPLAZ™ may help expand access to plasma transfusion in environments where traditional frozen plasma has historically been difficult to deliver. The approval also reflects years of scientific collaboration between industry, healthcare providers, and government agencies aimed at improving emergency care for patients experiencing life-threatening hemorrhage.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit www.teleflex.com.